WO2003029484A3 - Antimicrobial methods and materials - Google Patents

Antimicrobial methods and materials Download PDF

Info

Publication number
WO2003029484A3
WO2003029484A3 PCT/US2001/030379 US0130379W WO03029484A3 WO 2003029484 A3 WO2003029484 A3 WO 2003029484A3 US 0130379 W US0130379 W US 0130379W WO 03029484 A3 WO03029484 A3 WO 03029484A3
Authority
WO
WIPO (PCT)
Prior art keywords
materials
antimicrobial methods
microbes
gene products
methods
Prior art date
Application number
PCT/US2001/030379
Other languages
French (fr)
Other versions
WO2003029484A2 (en
Inventor
Che-Shen C Tomich
Cheryl L Quinn
Staffan Arvidson
John E Mott
Douglas W Harris
Original Assignee
Upjohn Co
Che-Shen C Tomich
Cheryl L Quinn
Staffan Arvidson
John E Mott
Douglas W Harris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Che-Shen C Tomich, Cheryl L Quinn, Staffan Arvidson, John E Mott, Douglas W Harris filed Critical Upjohn Co
Priority to JP2003532697A priority Critical patent/JP2005503831A/en
Priority to PCT/US2001/030379 priority patent/WO2003029484A2/en
Priority to EP01975530A priority patent/EP1432814A2/en
Publication of WO2003029484A2 publication Critical patent/WO2003029484A2/en
Publication of WO2003029484A3 publication Critical patent/WO2003029484A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods of identifying agents that bind gene products critical for the survival of microbes, preferably Staphylococcus microbes, including agents that interfere with the function of such gene products.
PCT/US2001/030379 2001-09-28 2001-09-28 Antimicrobial methods and materials WO2003029484A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003532697A JP2005503831A (en) 2001-09-28 2001-09-28 Antimicrobial methods and materials
PCT/US2001/030379 WO2003029484A2 (en) 2001-09-28 2001-09-28 Antimicrobial methods and materials
EP01975530A EP1432814A2 (en) 2001-09-28 2001-09-28 Antimicrobial methods and materials

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/030379 WO2003029484A2 (en) 2001-09-28 2001-09-28 Antimicrobial methods and materials

Publications (2)

Publication Number Publication Date
WO2003029484A2 WO2003029484A2 (en) 2003-04-10
WO2003029484A3 true WO2003029484A3 (en) 2003-07-31

Family

ID=21742872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030379 WO2003029484A2 (en) 2001-09-28 2001-09-28 Antimicrobial methods and materials

Country Status (3)

Country Link
EP (1) EP1432814A2 (en)
JP (1) JP2005503831A (en)
WO (1) WO2003029484A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311789D0 (en) * 2003-05-22 2003-06-25 Astrazeneca Ab Method

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001473A2 (en) * 1997-07-03 1999-01-14 Imperial College Innovations Limited Anti-bacterial methods and materials
WO1999032657A1 (en) * 1997-12-23 1999-07-01 Microcide Pharmaceuticals, Inc. Staphylococcus aureus histidine protein kinase essential genes
WO1999055729A1 (en) * 1998-04-27 1999-11-04 Smithkline Beecham Corporation STAPHYLOCOCCUS AUREUS pyrH POLYPEPTIDES AND POLYNUCLEOTIDES
WO2001002588A2 (en) * 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
WO2001016292A2 (en) * 1999-09-01 2001-03-08 Human Genome Sciences, Inc. 37 staphylococcus aureus genes and polypeptides
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
WO2001049775A2 (en) * 2000-01-04 2001-07-12 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
WO2001077365A2 (en) * 2000-04-06 2001-10-18 Pharmacia & Upjohn Company Antimicrobial methods and materials

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001473A2 (en) * 1997-07-03 1999-01-14 Imperial College Innovations Limited Anti-bacterial methods and materials
WO1999032657A1 (en) * 1997-12-23 1999-07-01 Microcide Pharmaceuticals, Inc. Staphylococcus aureus histidine protein kinase essential genes
WO1999055729A1 (en) * 1998-04-27 1999-11-04 Smithkline Beecham Corporation STAPHYLOCOCCUS AUREUS pyrH POLYPEPTIDES AND POLYNUCLEOTIDES
WO2001002588A2 (en) * 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
WO2001016292A2 (en) * 1999-09-01 2001-03-08 Human Genome Sciences, Inc. 37 staphylococcus aureus genes and polypeptides
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
WO2001049775A2 (en) * 2000-01-04 2001-07-12 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
WO2001077365A2 (en) * 2000-04-06 2001-10-18 Pharmacia & Upjohn Company Antimicrobial methods and materials

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KURODA M. ET AL.: "Whole genome sequencing of meticillin-resistant Staphylococcus aureus.", THE LANCET, vol. 357, 21 April 2001 (2001-04-21), pages 1225 - 1240, XP004246103 *
PUCCI M.J. ET AL.: "Identification and characterization of cell wall-cell division gene clusters in pathogenic gram-positive cocci.", J. BACTERIOL., vol. 179, no. 17, September 1997 (1997-09-01), pages 5632 - 5635, XP002098344 *
ROMINE M.F. ET AL.: "Complete sequence of a 184-kilobase catabolic plasmid from Sphingomonas aromaticivorans F199.", J. BACTERIOL., vol. 181, no. 5, March 1999 (1999-03-01), pages 1585 - 1602, XP002224644 *

Also Published As

Publication number Publication date
JP2005503831A (en) 2005-02-10
WO2003029484A2 (en) 2003-04-10
EP1432814A2 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
AU2002344842A1 (en) Highly impact-resistant granules
AU2001239725A1 (en) Antibacterial agents
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
WO2003066802A3 (en) Gene expression analysis using nicking agents
WO2002074293A3 (en) Methods for restoring cognitive function following systemic stress
AU2002327096A1 (en) 3-phenoxy-4-pyridazinol derivative and herbicide composition containing the same
AU2002308050A1 (en) Milieux de detection specific de staphylococcus aureus
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
WO2000034265A3 (en) Quinoline-indole antimicrobial agents
WO2003103732A3 (en) Antimicrobial polyolefin articles and methods for their preparation
EP2311466A3 (en) Antimicrobial compounds and methods for their use
MXPA05012929A (en) Aryl-heteroaromatic products, compositions containing same and use thereof.
AU2002364607A1 (en) Novel ligand involved in the transmigration of leukocytes .
WO2002005643A3 (en) Biocide compositions and methods and systems employing same
WO2004034961A3 (en) Antimicrobial agents and uses thereof
WO2002080855A3 (en) Methods and compounds for decreasing cell toxicity or death
WO2001077365A3 (en) Antimicrobial methods and materials
WO2003029484A3 (en) Antimicrobial methods and materials
WO2002072790A3 (en) Tsg101-gag interaction and use thereof
WO2004016640A3 (en) 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
WO2002094976A3 (en) Identification of antimicrobial agents
WO2008057067A3 (en) Biocidal materials
AU2002358356A1 (en) Mood messaging
AU2001282860A1 (en) Staphylococcus aureus ribosomal protein s20, corresponding gene and methods for the identification of antibacterial substances
AU2003289871A1 (en) 2-mercapto-substituted triazolopyrimidines, methods for the production thereof, the use of the same for controlling pathogenic fungi, and agents containing said compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003532697

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001975530

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001975530

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001975530

Country of ref document: EP